HYDERABAD: Bharat Biotech has partnered with Spanish biopharma player Biofabri to develop, manufacture and distribute a novel TB vaccine, MTBVAC, in more than 70 countries with a high TB incidence, primarily in Southeast Asia and sub-Saharan Africa.
The Phase III clinical trials of the vaccine are set to start in Senegal, South Africa and Madagascar in the second half of 2022, Bharat Biotech said on Wednesday.
